Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

Silence Therapeutics said data from its Phase 2 SANRECO study of divesiran, an siRNA therapy for polycythemia vera, was accepted for an oral presentation at the 68th ASH Annual Meeting, December 12–15, 2026, in New Orleans. The announcement provides no study results or clinical outcome figures.

Analysis

The investment question is not the conference slot but whether the dataset demonstrates clinically meaningful control of PV with a tolerable safety profile. A signal on phlebotomy burden or hematocrit control could support a differentiated treatment opportunity; weak durability, safety issues, or efficacy that does not compare favorably with existing options such as ruxolitinib or ropeginterferon would leave the program exposed to established care. Those are hypotheses to test against the actual data, not conclusions from acceptance of an abstract.

The December presentation is a defined near-term catalyst, but the announcement contains no efficacy, safety, trial-design, or commercial information from which to update probability of success or valuation. Expect event-driven volatility around abstract availability and the oral presentation; a conference presentation alone does not de-risk a Phase 2 asset. Over 6–18 months, follow-up durability and the path to a registrational study matter more than the presentation format. Financing exposure and the market’s expectations are also unknown and should be checked before taking a directional view.

Key Decisions for Investors

• No trade on the announcement alone. Track SLN into abstract release and the December presentation; avoid treating acceptance as evidence of positive results.
• Before positioning, verify trial size and design, prespecified endpoints, phlebotomy and hematocrit outcomes, safety, duration of follow-up, and any comparison with current PV treatment. These determine whether the result changes the commercial case.
• If the data show a clear, durable efficacy signal without a material safety concern, reassess SLN for a catalyst-driven long only after checking the stock’s move and expectations. If results are weak or safety limits use, avoid the long and reassess downside rather than shorting solely on the headline.
• Falsifiers for a bullish thesis are limited durability, inadequate control of disease measures, clinically relevant toxicity, or subsequent guidance that delays development. Also check cash runway and any financing plans; neither is established by this announcement.